Td Asset Management Inc Biomarin Pharmaceutical Inc Transaction History

Td Asset Management Inc

  • $102 Billion
  • Q2 2024

A detailed history of Td Asset Management Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Td Asset Management Inc holds 143,897 shares of BMRN stock, worth $10.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
143,897
Previous 158,621 9.28%
Holding current value
$10.2 Million
Previous $13.9 Million 14.48%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 02, 2024
SELL
$74.43 - $92.22 $1.1 Million - $1.36 Million
-14,724 Reduced 9.28%
143,897 $11.8 Million
Q1 2024

May 08, 2024
SELL
$83.81 - $99.0 $2.72 Million - $3.21 Million
-32,409 Reduced 16.97%
158,621 $13.9 Million
Q4 2023

Feb 12, 2024
BUY
$76.22 - $98.51 $1.36 Million - $1.76 Million
17,858 Added 10.31%
191,030 $18.4 Million
Q3 2023

Oct 27, 2023
BUY
$85.07 - $94.48 $6.19 Million - $6.87 Million
72,742 Added 72.43%
173,172 $15.3 Million
Q2 2023

Aug 09, 2023
SELL
$86.68 - $100.3 $246,084 - $284,751
-2,839 Reduced 2.75%
100,430 $8.71 Million
Q1 2023

May 10, 2023
BUY
$87.74 - $117.27 $2.09 Million - $2.79 Million
23,768 Added 29.9%
103,269 $10 Million
Q4 2022

Feb 06, 2023
BUY
$80.93 - $108.63 $1.98 Million - $2.66 Million
24,485 Added 44.51%
79,501 $8.23 Million
Q3 2022

Nov 07, 2022
BUY
$82.16 - $96.94 $456,070 - $538,113
5,551 Added 11.22%
55,016 $4.68 Million
Q2 2022

Aug 04, 2022
SELL
$71.48 - $86.85 $440,173 - $534,822
-6,158 Reduced 11.07%
49,465 $4.1 Million
Q1 2022

May 10, 2022
BUY
$74.28 - $92.69 $2.04 Million - $2.55 Million
27,485 Added 97.68%
55,623 $4.29 Million
Q4 2021

Feb 10, 2022
SELL
$71.72 - $91.47 $72,222 - $92,110
-1,007 Reduced 3.46%
28,138 $2.49 Million
Q3 2021

Nov 09, 2021
BUY
$74.77 - $85.47 $4,187 - $4,786
56 Added 0.19%
29,145 $2.25 Million
Q2 2021

Aug 11, 2021
SELL
$75.51 - $84.79 $2.64 Million - $2.97 Million
-35,000 Reduced 54.61%
29,089 $2.23 Million
Q1 2021

May 14, 2021
SELL
$74.73 - $90.69 $27,575 - $33,464
-369 Reduced 0.57%
64,089 $4.84 Million
Q4 2020

Feb 16, 2021
BUY
$72.61 - $90.2 $29,261 - $36,350
403 Added 0.63%
64,458 $5.65 Million
Q3 2020

Nov 10, 2020
SELL
$71.87 - $131.03 $511,067 - $931,754
-7,111 Reduced 9.99%
64,055 $4.87 Million
Q2 2020

Aug 13, 2020
BUY
$79.55 - $124.22 $196,647 - $307,071
2,472 Added 3.6%
71,166 $8.78 Million
Q1 2020

May 15, 2020
SELL
$71.37 - $96.85 $1.37 Million - $1.86 Million
-19,200 Reduced 21.84%
68,694 $5.81 Million
Q4 2019

Feb 11, 2020
BUY
$64.27 - $86.37 $213,119 - $286,402
3,316 Added 3.92%
87,894 $7.43 Million
Q3 2019

Nov 07, 2019
BUY
$67.4 - $85.11 $357,220 - $451,083
5,300 Added 6.69%
84,578 $5.7 Million
Q2 2019

Aug 01, 2019
SELL
$80.35 - $93.9 $830,256 - $970,268
-10,333 Reduced 11.53%
79,278 $6.79 Million
Q1 2019

May 08, 2019
BUY
$84.2 - $98.62 $677,894 - $793,989
8,051 Added 9.87%
89,611 $7.96 Million
Q4 2018

Feb 01, 2019
SELL
$80.14 - $106.07 $551,844 - $730,398
-6,886 Reduced 7.79%
81,560 $6.95 Million
Q3 2018

Nov 01, 2018
BUY
$93.92 - $105.72 $50,716 - $57,088
540 Added 0.61%
88,446 $8.58 Million
Q2 2018

Jul 31, 2018
BUY
$76.01 - $99.03 $1.07 Million - $1.4 Million
14,107 Added 19.12%
87,906 $8.28 Million
Q1 2018

May 11, 2018
SELL
$77.67 - $92.63 $327,922 - $391,083
-4,222 Reduced 5.41%
73,799 $5.98 Million
Q4 2017

Feb 02, 2018
BUY
$80.76 - $95.13 $274,341 - $323,156
3,397 Added 4.55%
78,021 $6.96 Million
Q3 2017

Nov 09, 2017
BUY
$80.6 - $94.95 $6.01 Million - $7.09 Million
74,624
74,624 $6.95 Million

Others Institutions Holding BMRN

# of Institutions
632
Shares Held
185M
Call Options Held
1.63M
Put Options Held
1.2M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email